Poxel S.A. (POXEL.PA)
EUR 0.13
(-0.94%)
EUR 0.13
(-0.94%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 46.9 Million EUR | 7.97% |
| 2022 | 43.43 Million EUR | 23.62% |
| 2021 | 35.14 Million EUR | 48.76% |
| 2020 | 23.62 Million EUR | 209.31% |
| 2019 | 7.63 Million EUR | -46.34% |
| 2018 | 14.23 Million EUR | 1793.85% |
| 2017 | 751.48 Thousand EUR | -13.73% |
| 2016 | 871.08 Thousand EUR | -72.31% |
| 2015 | 3.14 Million EUR | -27.84% |
| 2014 | 4.35 Million EUR | -81.88% |
| 2013 | 24.06 Million EUR | 606.04% |
| 2012 | 3.4 Million EUR | 561314.5% |
| 2011 | 607.00 EUR | -41.52% |
| 2010 | 1038.00 EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 Q2 | 46.82 Million EUR | 0.0% |
| 2023 FY | - EUR | -100.0% |
| 2023 Q4 | 46.9 Million EUR | 0.0% |
| 2022 Q2 | 33.99 Million EUR | 0.0% |
| 2022 Q4 | 43.43 Million EUR | 0.0% |
| 2022 FY | 43.43 Million EUR | 23.62% |
| 2021 FY | 35.14 Million EUR | 48.76% |
| 2021 Q4 | 35.14 Million EUR | 0.0% |
| 2021 Q2 | 37.03 Million EUR | 0.0% |
| 2020 Q4 | 23.62 Million EUR | 0.0% |
| 2020 FY | 23.62 Million EUR | 209.31% |
| 2020 Q2 | 17.58 Million EUR | 0.0% |
| 2019 Q2 | 9.86 Million EUR | 0.0% |
| 2019 Q4 | 7.63 Million EUR | 0.0% |
| 2019 FY | 7.63 Million EUR | -46.34% |
| 2018 Q2 | 670.53 Thousand EUR | 0.0% |
| 2018 FY | 14.23 Million EUR | 1793.85% |
| 2018 Q4 | 14.23 Million EUR | 0.0% |
| 2017 Q2 | 816.25 Thousand EUR | 0.0% |
| 2017 FY | 751.48 Thousand EUR | -13.73% |
| 2017 Q4 | 751.48 Thousand EUR | 0.0% |
| 2016 Q2 | 2.06 Million EUR | 0.0% |
| 2016 FY | 871.08 Thousand EUR | -72.31% |
| 2016 Q4 | 871.08 Thousand EUR | 0.0% |
| 2015 FY | 3.14 Million EUR | -27.84% |
| 2015 Q2 | 4.12 Million EUR | 0.0% |
| 2015 Q4 | 3.14 Million EUR | 0.0% |
| 2014 Q2 | 21.36 Million EUR | 0.0% |
| 2014 Q4 | 4.35 Million EUR | 0.0% |
| 2014 FY | 4.35 Million EUR | -81.88% |
| 2013 Q4 | 24.06 Million EUR | 0.0% |
| 2013 FY | 24.06 Million EUR | 606.04% |
| 2012 FY | 3.4 Million EUR | 561314.5% |
| 2011 FY | 607.00 EUR | -41.52% |
| 2010 FY | 1038.00 EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 3.39 Million EUR | -1283.481% |
| ABIVAX Société Anonyme | 55.46 Million EUR | 15.441% |
| Adocia SA | 13.08 Million EUR | -258.344% |
| Aelis Farma SA | 4.03 Million EUR | -1061.466% |
| Biophytis S.A. | 8.27 Million EUR | -467.11% |
| Advicenne S.A. | 17.42 Million EUR | -169.154% |
| genOway Société anonyme | 7.23 Million EUR | -548.381% |
| IntegraGen SA | 1.12 Million EUR | -4069.871% |
| Medesis Pharma S.A. | 1.2 Million EUR | -3808.333% |
| Neovacs S.A. | 650 Thousand EUR | -7115.385% |
| NFL Biosciences SA | 62.17 Thousand EUR | -75333.461% |
| Plant Advanced Technologies SA | 4.35 Million EUR | -976.55% |
| Quantum Genomics Société Anonyme | 2.71 Million EUR | -1626.271% |
| Sensorion SA | 2.86 Million EUR | -1534.837% |
| Theranexus Société Anonyme | 3.64 Million EUR | -1187.393% |
| TME Pharma N.V. | 1.16 Million EUR | -3922.298% |
| Valbiotis SA | 6.87 Million EUR | -581.884% |
| TheraVet SA | 1.15 Million EUR | -3943.567% |
| Valerio Therapeutics Société anonyme | 8.99 Million EUR | -421.227% |
| argenx SE | 18.1 Million EUR | -159.04% |
| BioSenic S.A. | 28.16 Million EUR | -66.542% |
| Celyad Oncology SA | 902 Thousand EUR | -5099.557% |
| DBV Technologies S.A. | 13.01 Million USD | -260.254% |
| Galapagos NV | 9.59 Million EUR | -388.745% |
| Genfit S.A. | 70.17 Million EUR | 33.17% |
| GeNeuro SA | 7.73 Million EUR | -506.115% |
| Hyloris Pharmaceuticals SA | 5.29 Million EUR | -785.909% |
| Innate Pharma S.A. | 39.89 Million EUR | -17.564% |
| Inventiva S.A. | 37.4 Million EUR | -25.378% |
| MaaT Pharma SA | 14.07 Million EUR | -233.215% |
| MedinCell S.A. | 58.96 Million EUR | 20.456% |
| Nanobiotix S.A. | 50.56 Million EUR | 7.248% |
| Onward Medical N.V. | 16.87 Million EUR | -177.942% |
| Oryzon Genomics S.A. | 13.68 Million EUR | -242.655% |
| OSE Immunotherapeutics SA | 45.8 Million EUR | -2.4% |
| Oxurion NV | 12.33 Million EUR | -280.25% |
| Pharming Group N.V. | 155.29 Million EUR | 69.799% |
| GenSight Biologics S.A. | 18.42 Million EUR | -154.504% |
| Transgene SA | 1.25 Million EUR | -3631.106% |
| Financière de Tubize SA | 79.2 Million EUR | 40.783% |
| UCB SA | 3.03 Billion EUR | 98.456% |
| Valneva SE | 208.81 Million EUR | 77.54% |
| Vivoryon Therapeutics N.V. | 38 Thousand EUR | -123321.053% |